KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.

David J Curtis, Sushrut S Patil, John Reynolds, Duncan Purtill, Clinton Lewis, David S Ritchie, David J Gottlieb, David T Yeung, Eric Wong, Siok-Keen Tey, Travis Perera, John Moore, Rachel M Koldej, Richard De Abreu Lourenco, John Stubbs, C Orla Morrissey, Nadia Munsef, Andrea Arenas, Geoffrey R Hill, Australasian Leukaemia and Lymphoma Group

N Engl J Med 393(3) 243-254

PMID40513032
PMCIDPMC13186568
DOI10.1056/NEJMoa2503189
发表日期2025-06-13
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Allogeneic peripheral-blood stem-cell transplantation (SCT) from a matched related donor after myeloablative conditioning is the preferred curative treatment for patients with high-risk blood cancers. The combination of a calcineurin inhibitor and an antimetabolite remains standard care for graft-versus-host disease (GVHD) prophylaxis in these patients. Data from two randomized trials have suggested that post-transplantation cyclophosphamide can reduce the risk of GVHD after SCT from a matched donor when it is added to or replaces the antimetabolite. However, the effects of post-transplantation cyclophosphamide specifically after SCT from a matched related donor remain uncertain, and effects in the context of myeloablative conditioning are unclear. METHODS: We randomly assigned adults who were undergoing SCT from a matched related donor after myeloablative or reduced-intensity conditioning to receive either post-transplantation cyclophosphamide-cyclosporin (experimental prophylaxis) or cyclosporin-methotrexate (standard prophylaxis). The primary end point was GVHD-free, relapse-free survival. RESULTS: Among 134 patients who underwent randomization, 66 were assigned to receive experimental prophylaxis and 68 to receive standard prophylaxis. GVHD-free, relapse-free survival was significantly longer with experimental prophylaxis (median, 26.2 months; 95% confidence interval [CI], 9.1 to not reached) than with standard prophylaxis (median, 6.4 months; 95% CI, 5.6 to 8.3; P<0.001 by a log-rank test). GVHD-free, relapse-free survival at 3 years was 49% (95% CI, 36 to 61) with experimental prophylaxis and 14% (95% CI, 6 to 25) with standard prophylaxis (hazard ratio for GVHD, relapse, or death, 0.42; 95% CI, 0.27 to 0.66). The cumulative incidence of grade III to IV acute GVHD at 3 months was 3% (95% CI, 1 to 10) in the experimental-prophylaxis group and 10% (95% CI, 4 to 19) in the standard-prophylaxis group. At 2 years, overall survival was 83% and 71%, respectively (hazard ratio for death, 0.59; 95% CI, 0.29 to 1.19). The incidence of serious adverse events was similar in the two groups in the first 100 days after SCT. CONCLUSIONS: The combination of post-transplantation cyclophosphamide and a calcineurin inhibitor led to longer GVHD-free, relapse-free survival than standard prophylaxis after transplantation from a matched related donor with either reduced-intensity or myeloablative conditioning in patients with blood cancers. (Funded by the Australian Government Medical Research Future Fund and others; ALLG BM12 CAST Australian-New Zealand Clinical Trials Registry number, ACTRN12618000505202.).

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2.. Kaplan-Meier probability curves by treatment arm for primary and secondary endpoints in the full analysis set. Panel A shows the percent of patients for the primary endpoint of GVHD-free, relapse-free survival (GRFS). Numbers at risk in each group are shown below. Panel B shows the percent of patients for the post-hoc analysis endpoint of relapse-free survival (RFS). Panel C shows the percent of patients for the secondary endpoint of overall survival (OS).

Panel_A_GVHD-free_relapse-free_survival_GRFS_

GVHD-free, relapse-free survival (GRFS)

Figure 2 · Panel Panel_A_GVHD-free_relapse-free_survival_GRFS_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Panel_A_GVHD-free_relapse-free_survival_GRFS_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Disposition of all randomized patients according to treatment arm at time of analysis. Number of patients shown and percentage for each group shown in parentheses. Details of the 5 patients not transplanted are shown in Table S3.
非 KM Figure